| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 30 | 2022 | 2903 | 2.120 |
Why?
|
| Liver Failure, Acute | 2 | 2021 | 98 | 0.850 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 7 | 2022 | 205 | 0.820 |
Why?
|
| Hyperuricemia | 1 | 2017 | 49 | 0.580 |
Why?
|
| Asparaginase | 4 | 2017 | 186 | 0.500 |
Why?
|
| Gene Order | 1 | 2010 | 109 | 0.370 |
Why?
|
| Anthracyclines | 3 | 2020 | 339 | 0.370 |
Why?
|
| Histone-Lysine N-Methyltransferase | 5 | 2021 | 462 | 0.350 |
Why?
|
| Infant | 29 | 2022 | 13970 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2021 | 16612 | 0.340 |
Why?
|
| Craniospinal Irradiation | 2 | 2021 | 133 | 0.310 |
Why?
|
| Cardiomyopathies | 3 | 2020 | 560 | 0.290 |
Why?
|
| Acute Disease | 4 | 2021 | 2517 | 0.280 |
Why?
|
| Child | 30 | 2021 | 30559 | 0.270 |
Why?
|
| Medulloblastoma | 2 | 2021 | 586 | 0.230 |
Why?
|
| Methotrexate | 4 | 2019 | 1033 | 0.230 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 642 | 0.220 |
Why?
|
| Child, Preschool | 22 | 2021 | 17056 | 0.220 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2002 | 75 | 0.200 |
Why?
|
| Idarubicin | 1 | 2003 | 459 | 0.190 |
Why?
|
| Drug Hypersensitivity | 3 | 2017 | 134 | 0.190 |
Why?
|
| Carbazoles | 1 | 2021 | 92 | 0.180 |
Why?
|
| Pneumonia, Bacterial | 1 | 2002 | 135 | 0.180 |
Why?
|
| Opportunistic Infections | 1 | 2002 | 237 | 0.180 |
Why?
|
| Polymorphism, Genetic | 3 | 2011 | 1559 | 0.180 |
Why?
|
| Bacterial Proteins | 2 | 2017 | 1094 | 0.170 |
Why?
|
| Scoliosis | 1 | 2021 | 148 | 0.170 |
Why?
|
| Infant, Newborn | 10 | 2017 | 8612 | 0.160 |
Why?
|
| Survivors | 7 | 2017 | 1025 | 0.160 |
Why?
|
| Glutathione Transferase | 1 | 2020 | 371 | 0.160 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2018 | 95 | 0.160 |
Why?
|
| Immunocompromised Host | 2 | 2005 | 721 | 0.160 |
Why?
|
| Humans | 49 | 2022 | 272087 | 0.150 |
Why?
|
| Erwinia | 1 | 2017 | 6 | 0.150 |
Why?
|
| Ribavirin | 1 | 2018 | 177 | 0.150 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2017 | 40 | 0.150 |
Why?
|
| Male | 36 | 2021 | 129088 | 0.150 |
Why?
|
| Mercaptopurine | 1 | 2017 | 131 | 0.150 |
Why?
|
| Philadelphia Chromosome | 1 | 2021 | 836 | 0.150 |
Why?
|
| Photons | 1 | 2021 | 537 | 0.140 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2021 | 842 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2019 | 1351 | 0.140 |
Why?
|
| Disease-Free Survival | 4 | 2014 | 10259 | 0.140 |
Why?
|
| Uric Acid | 1 | 2017 | 121 | 0.140 |
Why?
|
| Allopurinol | 1 | 2017 | 87 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2018 | 211 | 0.140 |
Why?
|
| Adolescent | 20 | 2020 | 32730 | 0.140 |
Why?
|
| CELF Proteins | 1 | 2016 | 14 | 0.130 |
Why?
|
| Female | 36 | 2021 | 149288 | 0.130 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2018 | 582 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 1772 | 0.130 |
Why?
|
| Life Style | 1 | 2019 | 623 | 0.130 |
Why?
|
| Cerebellar Neoplasms | 1 | 2021 | 486 | 0.130 |
Why?
|
| Antineoplastic Agents | 7 | 2016 | 14653 | 0.130 |
Why?
|
| Protons | 1 | 2018 | 483 | 0.130 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 522 | 0.130 |
Why?
|
| Neoplasms | 6 | 2020 | 15930 | 0.130 |
Why?
|
| Ikaros Transcription Factor | 1 | 2015 | 53 | 0.130 |
Why?
|
| Health Promotion | 1 | 2019 | 510 | 0.130 |
Why?
|
| Aftercare | 1 | 2017 | 255 | 0.130 |
Why?
|
| Cancer Survivors | 2 | 2020 | 744 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2018 | 320 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2017 | 550 | 0.130 |
Why?
|
| Translocation, Genetic | 3 | 2009 | 1288 | 0.120 |
Why?
|
| Induction Chemotherapy | 2 | 2016 | 671 | 0.120 |
Why?
|
| Pediatric Obesity | 1 | 2019 | 379 | 0.120 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2011 | 105 | 0.120 |
Why?
|
| Leukocyte Transfusion | 1 | 2014 | 44 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2002 | 709 | 0.110 |
Why?
|
| Age Factors | 5 | 2018 | 5526 | 0.110 |
Why?
|
| Pyrroles | 2 | 2018 | 592 | 0.110 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2014 | 163 | 0.110 |
Why?
|
| Glucuronosyltransferase | 1 | 2014 | 105 | 0.110 |
Why?
|
| Granulocytes | 1 | 2014 | 243 | 0.110 |
Why?
|
| Gene Rearrangement | 2 | 2014 | 817 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2010 | 6987 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1972 | 0.100 |
Why?
|
| Prednisolone | 1 | 2012 | 134 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 605 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 3671 | 0.100 |
Why?
|
| Daunorubicin | 1 | 2012 | 314 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2013 | 802 | 0.090 |
Why?
|
| Genotype | 4 | 2014 | 4267 | 0.090 |
Why?
|
| Models, Biological | 1 | 2019 | 3223 | 0.090 |
Why?
|
| Risk Factors | 7 | 2021 | 18051 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2009 | 413 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 745 | 0.090 |
Why?
|
| Models, Genetic | 2 | 2011 | 1169 | 0.090 |
Why?
|
| Survival Rate | 2 | 2014 | 12534 | 0.090 |
Why?
|
| Brain Neoplasms | 2 | 2004 | 4994 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2020 | 5756 | 0.090 |
Why?
|
| Papillomavirus Vaccines | 1 | 2012 | 196 | 0.080 |
Why?
|
| Body Height | 1 | 2010 | 235 | 0.080 |
Why?
|
| Neutropenia | 1 | 2014 | 1001 | 0.080 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 342 | 0.080 |
Why?
|
| Peroxidase | 1 | 2009 | 135 | 0.080 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2011 | 244 | 0.080 |
Why?
|
| Folic Acid | 1 | 2011 | 371 | 0.080 |
Why?
|
| Cranial Irradiation | 1 | 2010 | 322 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 330 | 0.080 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2009 | 189 | 0.080 |
Why?
|
| Cognition Disorders | 2 | 2011 | 774 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2400 | 0.080 |
Why?
|
| Pediatrics | 1 | 2017 | 1187 | 0.080 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NAD+) | 1 | 2007 | 4 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2016 | 1184 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1423 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 3856 | 0.070 |
Why?
|
| Hemoglobin SC Disease | 1 | 2007 | 14 | 0.070 |
Why?
|
| Transcription Factors | 3 | 2011 | 5506 | 0.070 |
Why?
|
| Tricuspid Atresia | 1 | 2007 | 14 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2012 | 1497 | 0.070 |
Why?
|
| Terminal Care | 1 | 2011 | 465 | 0.070 |
Why?
|
| Remission Induction | 2 | 2010 | 3645 | 0.070 |
Why?
|
| Autophagy | 1 | 2013 | 922 | 0.070 |
Why?
|
| Recurrence | 1 | 2014 | 4887 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 4640 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 4963 | 0.060 |
Why?
|
| Esophageal Diseases | 1 | 2005 | 79 | 0.060 |
Why?
|
| Paresis | 2 | 2021 | 55 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 5187 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2012 | 1014 | 0.060 |
Why?
|
| Medical Oncology | 2 | 2011 | 1464 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 2035 | 0.060 |
Why?
|
| Case-Control Studies | 4 | 2016 | 6236 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 15279 | 0.050 |
Why?
|
| Hodgkin Disease | 1 | 2011 | 1488 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 2198 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2003 | 64 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 2496 | 0.050 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2005 | 290 | 0.050 |
Why?
|
| Incidence | 3 | 2021 | 5864 | 0.050 |
Why?
|
| Myeloproliferative Disorders | 1 | 2009 | 881 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2007 | 847 | 0.050 |
Why?
|
| Decision Trees | 1 | 2002 | 180 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2019 | 2867 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 1913 | 0.050 |
Why?
|
| Hemiplegia | 1 | 2021 | 48 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 2452 | 0.050 |
Why?
|
| Karyotyping | 2 | 2015 | 1064 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2022 | 33909 | 0.050 |
Why?
|
| Furans | 1 | 2021 | 103 | 0.050 |
Why?
|
| Time Factors | 2 | 2012 | 13139 | 0.050 |
Why?
|
| Adult | 10 | 2017 | 81933 | 0.050 |
Why?
|
| Indoles | 2 | 2018 | 1034 | 0.040 |
Why?
|
| Leukemia | 1 | 2009 | 1721 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2011 | 5067 | 0.040 |
Why?
|
| Germ Cells | 1 | 2022 | 351 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 2014 | 738 | 0.040 |
Why?
|
| Apoptosis | 1 | 2013 | 7837 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2018 | 39831 | 0.040 |
Why?
|
| Precision Medicine | 2 | 2019 | 1207 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2007 | 1163 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2020 | 227 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2018 | 398 | 0.040 |
Why?
|
| Quality of Life | 1 | 2011 | 4755 | 0.040 |
Why?
|
| Multigene Family | 1 | 2018 | 465 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2015 | 2319 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 247 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2004 | 1039 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 5107 | 0.030 |
Why?
|
| Chromosome Fragility | 1 | 1996 | 33 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2011 | 2270 | 0.030 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 1996 | 53 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 13993 | 0.030 |
Why?
|
| Pancytopenia | 1 | 1996 | 119 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 1095 | 0.030 |
Why?
|
| Palliative Care | 1 | 2007 | 2161 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 3543 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2018 | 1035 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 4352 | 0.030 |
Why?
|
| Syndrome | 2 | 2009 | 1407 | 0.030 |
Why?
|
| Hyaluronan Synthases | 1 | 2014 | 17 | 0.030 |
Why?
|
| Troponin T | 1 | 2016 | 263 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2014 | 9500 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2011 | 1264 | 0.030 |
Why?
|
| North America | 2 | 2005 | 341 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 2355 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2020 | 1159 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 860 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 4003 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2017 | 682 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 10750 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 915 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 5421 | 0.020 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2011 | 42 | 0.020 |
Why?
|
| Surveys and Questionnaires | 3 | 2012 | 5935 | 0.020 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2011 | 26 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2011 | 66 | 0.020 |
Why?
|
| Young Adult | 3 | 2016 | 22142 | 0.020 |
Why?
|
| Necrosis | 1 | 2013 | 604 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 14881 | 0.020 |
Why?
|
| Algorithms | 1 | 2002 | 3925 | 0.020 |
Why?
|
| Drug Approval | 1 | 2011 | 176 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 393 | 0.020 |
Why?
|
| Hospice Care | 1 | 2011 | 161 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2011 | 243 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2011 | 322 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 9101 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 1327 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 7258 | 0.020 |
Why?
|
| Research | 1 | 2011 | 431 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2015 | 1310 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2005 | 5603 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 1074 | 0.020 |
Why?
|
| Health Policy | 1 | 2011 | 281 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 1011 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2009 | 225 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 2036 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2005 | 4890 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 2009 | 224 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 3072 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 1077 | 0.020 |
Why?
|
| United States | 2 | 2018 | 16066 | 0.020 |
Why?
|
| Folic Acid Antagonists | 1 | 2007 | 48 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 681 | 0.020 |
Why?
|
| Exome | 1 | 2012 | 1252 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 2333 | 0.020 |
Why?
|
| Prognosis | 3 | 2011 | 22555 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 505 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1547 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 1134 | 0.020 |
Why?
|
| Neprilysin | 1 | 2006 | 64 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2005 | 69 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 6885 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 653 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 1338 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2011 | 1260 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 7792 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 813 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2007 | 371 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 1905 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 3980 | 0.010 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2003 | 17 | 0.010 |
Why?
|
| Mutation | 2 | 2015 | 15944 | 0.010 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2003 | 37 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2011 | 2139 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 1342 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 1741 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 2365 | 0.010 |
Why?
|
| Consciousness Disorders | 1 | 2003 | 27 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 1373 | 0.010 |
Why?
|
| Blood Component Transfusion | 1 | 2003 | 89 | 0.010 |
Why?
|
| Cause of Death | 1 | 2006 | 787 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 3512 | 0.010 |
Why?
|
| ADAMTS13 Protein | 1 | 2003 | 71 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 5196 | 0.010 |
Why?
|
| ADAM Proteins | 1 | 2003 | 114 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 176 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 4513 | 0.010 |
Why?
|
| Plasma | 1 | 2003 | 147 | 0.010 |
Why?
|
| Plasma Exchange | 1 | 2003 | 103 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6270 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 3262 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 2003 | 189 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2009 | 1469 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 1994 | 0.010 |
Why?
|
| Neutrophils | 1 | 2005 | 876 | 0.010 |
Why?
|
| Middle Aged | 3 | 2015 | 90460 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 12223 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 1589 | 0.010 |
Why?
|
| Parents | 1 | 2007 | 1072 | 0.010 |
Why?
|
| Health Status | 1 | 2004 | 634 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 3472 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 1548 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 9046 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 5001 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2003 | 600 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 433 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 6210 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2011 | 3546 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2009 | 9326 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 5118 | 0.010 |
Why?
|
| Prevalence | 1 | 2004 | 3427 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2003 | 850 | 0.010 |
Why?
|
| Texas | 1 | 2003 | 6440 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1996 | 2446 | 0.000 |
Why?
|